Reference is made to the stock exchange announcement published today, 17
December 2025, regarding the preliminary results of the private placement of new
shares (the "Private Placement") in Inify Laboratories AB (publ) (the
"Company"), where it was announced that the Company will carry out a fully
guaranteed repair issue of new shares in the Company with gross proceeds of
approximately NOK 8 million (the "Repair Issue").

The Repair Issue will, subject to applicable securities law, be directed pro
-rata towards all existing shareholders in the Company, other than the
shareholders eligible to take part in the Private Placement, as of 16 December
2025 (as registered in Euronext Securities Oslo (the "VPS") or Euroclear, as
applicable, on 18 December 2025 (the "Record Date")), who are not resident in a
jurisdiction where such offering would be unlawful or would require any
prospectus, filing, registration or similar action. Shareholders with shares
registered with the VPS as of the Record Date will receive non-tradable
subscription rights to subscribe new shares in the Repair Issue. Shareholders
with shares registered directly with Euroclear as of the Record Date will not
receive any subscription rights. Instead, such shareholders will receive an
application form which shall be used to apply for subscription for shares in the
Repair Issue.

The following key information is provided with respect to the Repair Issue:

Date on which the terms and conditions of the Repair Issue were announced: 17
December 2025

Last day of trading including right to participate in the Repair Issue: 16
December 2025

First day of trading exclusive right to participate in the Repair Issue (ex
-date): 17 December 2025

Record Date: 18 December 2025

Date of approval: On or around 27 January 2026

Maximum number of new shares in the Repair Issue: 2,304,563

Subscription price: NOK 3.50 per share

This information is published in accordance with the requirements of the
Continuing Obligations.

For further information, please contact CEO, Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com

###

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Stockholm, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo (https://live.euronext.com/en/product/equities/SE0017486103
-MERK) under the ticker
INIFY. (https://live.euronext.com/en/product/equities/SE0017486103-MERK)